ATE540039T1 - Neue derivate von (verbrücktes piperazinyl)-1- alcanon und deren verwendung als p75-inhibitoren - Google Patents

Neue derivate von (verbrücktes piperazinyl)-1- alcanon und deren verwendung als p75-inhibitoren

Info

Publication number
ATE540039T1
ATE540039T1 AT09761939T AT09761939T ATE540039T1 AT E540039 T1 ATE540039 T1 AT E540039T1 AT 09761939 T AT09761939 T AT 09761939T AT 09761939 T AT09761939 T AT 09761939T AT E540039 T1 ATE540039 T1 AT E540039T1
Authority
AT
Austria
Prior art keywords
alcanone
inhibitors
new derivatives
bridged piperazinyl
piperazinyl
Prior art date
Application number
AT09761939T
Other languages
English (en)
Inventor
Marco Baroni
Francoise Bono
Sandrine Delbary-Gossart
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE540039T1 publication Critical patent/ATE540039T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT09761939T 2008-06-13 2009-06-12 Neue derivate von (verbrücktes piperazinyl)-1- alcanon und deren verwendung als p75-inhibitoren ATE540039T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0803299A FR2932482B1 (fr) 2008-06-13 2008-06-13 Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
PCT/FR2009/051118 WO2009150388A1 (fr) 2008-06-13 2009-06-12 NOUVEAUX DERIVES DE (PIPERAZINYL PONTE)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75

Publications (1)

Publication Number Publication Date
ATE540039T1 true ATE540039T1 (de) 2012-01-15

Family

ID=40305395

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09761939T ATE540039T1 (de) 2008-06-13 2009-06-12 Neue derivate von (verbrücktes piperazinyl)-1- alcanon und deren verwendung als p75-inhibitoren

Country Status (39)

Country Link
US (2) US8193190B2 (de)
EP (1) EP2297148B8 (de)
JP (1) JP5476373B2 (de)
KR (1) KR101642526B1 (de)
CN (1) CN102124006B (de)
AR (1) AR072103A1 (de)
AT (1) ATE540039T1 (de)
AU (1) AU2009259121B2 (de)
BR (1) BRPI0915126B8 (de)
CA (1) CA2727669C (de)
CL (1) CL2010001429A1 (de)
CO (1) CO6280535A2 (de)
CR (1) CR11832A (de)
CY (1) CY1112610T1 (de)
DK (1) DK2297148T3 (de)
DO (2) DOP2010000380A (de)
EA (1) EA019074B1 (de)
EC (1) ECSP10010672A (de)
ES (1) ES2379685T3 (de)
FR (1) FR2932482B1 (de)
HK (1) HK1158631A1 (de)
HR (1) HRP20120290T1 (de)
IL (1) IL209902A (de)
JO (1) JO2774B1 (de)
MA (1) MA32474B1 (de)
MX (1) MX2010013695A (de)
MY (1) MY150988A (de)
NI (1) NI201000215A (de)
NZ (1) NZ589840A (de)
PE (1) PE20110154A1 (de)
PL (1) PL2297148T3 (de)
PT (1) PT2297148E (de)
RS (1) RS52262B (de)
SI (1) SI2297148T1 (de)
SV (1) SV2010003755A (de)
TW (1) TWI432433B (de)
UA (1) UA101979C2 (de)
UY (1) UY31893A (de)
WO (1) WO2009150388A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931223B1 (fr) 2008-05-16 2010-08-20 Air Liquide Dispositif distributeur de gaz sous pression, ensemble comprenant un tel dispositif et dispositif de commande, recipient pourvu d'un tel dispositif distributeur
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (de) 2011-12-20 2013-06-26 Sanofi Neuartige therapeutische Verwendung von p75-Rezeptorantagonisten

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3236243A1 (de) * 1982-09-30 1984-04-05 Merck Patent Gmbh, 6100 Darmstadt Schwefelhaltige indolderivate
FR2744448B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) * 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
WO2000059893A1 (en) 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
DOP2013000124A (es) 2013-12-31
RS52262B (en) 2012-10-31
NI201000215A (es) 2011-05-04
PL2297148T3 (pl) 2012-05-31
KR101642526B1 (ko) 2016-07-25
CR11832A (es) 2011-02-04
BRPI0915126B8 (pt) 2021-05-25
KR20110018435A (ko) 2011-02-23
DOP2010000380A (es) 2011-01-15
UA101979C2 (ru) 2013-05-27
EA019074B1 (ru) 2013-12-30
WO2009150388A1 (fr) 2009-12-17
AU2009259121A1 (en) 2009-12-17
MA32474B1 (fr) 2011-07-03
TW201002710A (en) 2010-01-16
UY31893A (es) 2010-01-29
JP5476373B2 (ja) 2014-04-23
SI2297148T1 (sl) 2012-05-31
AU2009259121B2 (en) 2013-12-19
JO2774B1 (en) 2014-03-15
EP2297148B1 (de) 2012-01-04
JP2011522869A (ja) 2011-08-04
CY1112610T1 (el) 2016-02-10
US20110144116A1 (en) 2011-06-16
US20120232280A1 (en) 2012-09-13
HRP20120290T1 (hr) 2012-04-30
EP2297148A1 (de) 2011-03-23
US8519143B2 (en) 2013-08-27
NZ589840A (en) 2012-11-30
CA2727669A1 (fr) 2009-12-17
FR2932482A1 (fr) 2009-12-18
EA201170016A1 (ru) 2011-08-30
US8193190B2 (en) 2012-06-05
BRPI0915126A2 (pt) 2016-02-16
TWI432433B (zh) 2014-04-01
FR2932482B1 (fr) 2010-10-08
ECSP10010672A (es) 2011-01-31
AR072103A1 (es) 2010-08-04
PE20110154A1 (es) 2011-03-14
IL209902A0 (en) 2011-02-28
BRPI0915126B1 (pt) 2019-09-24
CA2727669C (fr) 2016-08-23
ES2379685T3 (es) 2012-04-30
SV2010003755A (es) 2011-03-15
HK1158631A1 (en) 2012-07-20
MY150988A (en) 2014-03-31
CO6280535A2 (es) 2011-05-20
CL2010001429A1 (es) 2011-07-29
IL209902A (en) 2014-09-30
MX2010013695A (es) 2011-03-04
DK2297148T3 (da) 2012-05-07
EP2297148B8 (de) 2012-03-28
PT2297148E (pt) 2012-04-03
CN102124006A (zh) 2011-07-13
CN102124006B (zh) 2014-06-11

Similar Documents

Publication Publication Date Title
DE602007013295D1 (de) Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
DK2193118T3 (da) Piperidin- og piperazinderivater til behandling af tumorer
ATE546433T1 (de) Quinolinderivate und ihre verwendung als fungizide
ATE472543T1 (de) Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
ATE472546T1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
ATE548355T1 (de) 4- (4-cyano-2-thioaryl) -dihydropyrimidinone und ihre verwendung
BRPI0906980A2 (pt) Composição de derivados e maleatados
DE502008001903D1 (de) 2 -heteroaryl- pyrrolo ä3, 4-cüpyrrol- derivate und deren verwendung als scd inhibitoren
DE102008063992A8 (de) Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
ATE553084T1 (de) Polycyclische säureverbindungen als crth2- antagonisten und antiallergika
DE602005006744D1 (de) Chinolinderivate zur verwendung als inhibitoren von mycobakterien
ATE531712T1 (de) Substituierte aryloxazole und ihre verwendung
DE112007000789A5 (de) Verwendung von Bora-tetraazepentalenen
ATE486856T1 (de) Benzimidazol-derivate und ihre verwendung zur modulierung des gabaa-rezeptor-komplexes
DE602005006101D1 (de) Substituierte chinoline und deren verwendung als inhibitoren von mycobakterien
ATE513822T1 (de) Benzothiazepinderivate und ihre verwendung als modulatoren von ampa und nmda rezeptoren
ATE540755T1 (de) Verwendung von katalysatorzusammensetzungen und verfahren zur oxychlorierung
ATE478059T1 (de) Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
DE602007011897D1 (de) Neue aminoalkohol-substituierte aryldihydroisochinolinone, herstellungsverfahren und ihre verwendung als medikamente
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
ATE540682T1 (de) Kombination von triazin-derivaten und insulin- sekretionsstimulatoren
DE602005017500D1 (de) Herstellungsverfahren für 2-substituierte derivate von östron und östradiol
ATE540039T1 (de) Neue derivate von (verbrücktes piperazinyl)-1- alcanon und deren verwendung als p75-inhibitoren
ATE468338T1 (de) Pyrrolochinolinderivate und ihre verwendung als proteinkinasehemmer
DE602006015735D1 (de) Bodenbeschichtungszusammensetzung und Verwendung eines Zusatzes für Bodenbeschichtungszusammensetzung